HOUSTON, TX - (http://www.financialnewsmedia.com News Alert) - Moleculin Biotech, Inc., (NASDAQ: MBRX) (\"Moleculin\" or the \"Company\"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced its scientific presentation at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Waldemar Priebe, PhD, Moleculin\'s Founder, Founding Scientist, and Chair of the Scientific Advisory Board presented the Abstract on November 30th at the Symposium in Munich, Germany.



Wally Klemp, Chairman and CEO stated, \"This presentation shows proof of concept data for our WP1122 portfolio, including data demonstrating increased survival of animals with human brain tumors treated with WP1122, as well as its biodistribution and pharmacokinetics. In non-optimal doses and treatment regimens, our lead inhibitor WP1122 performed equal to or better than the current market leader, cytotoxic drug temozolomide and significantly improved survival in animals treated with WP1122 in combination with temozolomide.\" Read this and more news for MBRX at http://financialnewsmedia.com/profiles/mbrx.html



The following is an overview of the presentation, titled \"Latentiation of 2-deoxy-D-glucose\". No curative therapy exists for patients with high-grade malignant gliomas (GBMs). New approaches to the treatment of this disease are currently being evaluated with mixed results. One approach, that deserves to be therapeutically exploited, is targeting brain tumor metabolism. 2-Deoxy-D-glucose (2-DG), a known effective inhibitor of glycolysis, has been clinically tested but results did not meet expectations due to poor drug-like characteristics and inability to achieve therapeutic concentrations of 2-DG in the brain.



Dr. Waldemar Priebe stated, \"We proposed to use latentiation of 2-DG to overcome this problem by chemically modifying biologically active 2-DG to form prodrugs with increased brain uptake that will be able to liberate in vivo the parent compound 2-DG in the brain. In our approach, we synthesized a series of differentially acetylated derivatives of 2-DG. Preliminary...